AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 9 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Giving high-dose interferon therapy with the GM2-KLH/QS-21 (GMK) vaccine does not inhibit immune response and appears to prolong relapse-free survival in high-risk melanoma patients.
High-dose interferon alfa 2b (IFN alpha 2b) is the only established adjuvant therapy of resectable high-risk melanoma, while GMK is one of the best vaccine candidates for the disease.
J.M. Kirkwood and colleagues at the University of Pittsburgh Medical Center, Pennsylvania, proposed that both given together might be more effective than either alone.
Their Phase II study evaluated the combination of GMK and IFN alpha 2b in resectable high-risk American Joint Committee on Cancer (AJCC) stage IIB or III melanoma in 107 patients.
The researchers found that IFN alpha 2b does not significantly inhibit immune response to the vaccine and that the combination is well-tolerated. Furthermore, the dual therapy appears to prolong relapse-free survival in this patient group ("High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multi-center Eastern Cooperative Oncology Group Phase II trial E2696," Journal of Clinical Oncology, 2001;19(5):1430-1436).
"Cox ...